Alpex Acquisition Corp.

ALPX is still in a tight base, trading just above its 200-day average and near the top of a very narrow yearly range. That setup favors a neutral-to-positive regime, but the stock has not yet broken into a sustained trend.

No analyst consensus or price target is on file, and there have been no recent rating changes. The setup is effectively unloved by the Street, so any rerating would need to come from clinical progress rather than target revisions.

No earnings estimates or beat-rate history are available, so the next report is more of a catalyst check than a consensus test. Shareholders should watch for updates on clinical milestones, cash runway, and whether operating losses are narrowing.

No notable insider buying or selling in recent quarters. With no reported transactions, there is no clear discretionary signal from management to anchor near-term sentiment.

Profitability is not yet established, and the latest cash flow profile remains negative with operating cash flow of -$281,037 and free cash flow of -$281,037. The balance sheet is light, with $40,208 in cash against $200,000 of debt, leaving net debt of $159,792.

As a clinical-stage biotech, ALPX competes on pipeline optionality rather than current earnings power, so it screens more like a development story than a cash-generating peer. With no valuation multiples on file, the stock is hard to benchmark on traditional sector metrics.